Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs, announced today the successful results of the company’s Phase IIb pivotal study of P2B001 for the treatment of early stage Parkinson’s Disease (PD).

Follow this link:
Pharma Two B reports positive results from P2B001 Phase IIb study for treatment of early stage PD

Scroll to Top